MaxCyte Seeks to Dual-List on NASDAQ

MaxCyte, Inc. has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market.

The number of securities to be offered and the price for the proposed Offering have not yet been determined.

MaxCyte is currently listed on the London Exchange.

The company is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization.

You May Also Be Interested In

• Vincerx Pharma (VINC) Announces Proposed Share and Warrant Offering
• Business First Bancshares Inc. (BFST) to acquire Oakwood Bancshares
• INmune Bio (INMB) Prices 986K Share Offering at $9.84/sh